BEIJING, July 25 (Xinhua) -- AstraZeneca is intensifying its commitment to China, deepening investments in research, manufacturing, and partnerships as the British pharmaceutical company seeks to tap into the opportunities presented by the country's rise as a global hub for healthcare innovation.
"We are really trying to broaden and expand our partnership in China," Iskra Reic, AstraZeneca executive vice president, international, told Xinhua in a recent interview.
Noting that China is a global leader in healthcare innovation, she said the number of medicines developed in China at AstraZeneca has doubled over the last four years.
The company's local footprint has grown substantially since entering the Chinese market in 1993. It has established global production hubs in the cities of Wuxi, Taizhou and Qingdao, which supply high-quality medicines to more than 70 markets worldwide.
Earlier this year, the company announced an investment of $2.5 billion to establish a global strategic R&D center in Beijing, following the one set up in Shanghai a few years ago.
AstraZeneca's push in China aligns with its broader goals to help advance the Healthy China 2030 initiative and expand access to quality healthcare. Focusing on therapeutic areas where Chinese patients have the most urgent needs, it has introduced over 40 innovative drugs to China.
Collaboration with Chinese innovators is also a key component of AstraZeneca's strategy. Over the past two years, it has signed global licensing agreements with 14 Chinese biotech companies. Through its healthcare investment fund, the company is also supporting 27 Chinese biotechs in their global expansion efforts.
These progresses, she noted, reflect AstraZeneca's "sustained commitment to China and our confidence in its innovation."
The company has attended the China International Supply Chain Expo for three consecutive years, highlighting its China partnership and vision for a sustainable, healthy future.
"We truly believe that China's innovation in the healthcare space can make a huge impact to tackle global healthcare challenges in the years to come," she added.
BEIJING, July 25 (Xinhua) -- AstraZeneca is intensifying its commitment to China, deepening investments in research, manufacturing, and partnerships as the British pharmaceutical company seeks to tap into the opportunities presented by the country's rise as a global hub for healthcare innovation.
"We are really trying to broaden and expand our partnership in China," Iskra Reic, AstraZeneca executive vice president, international, told Xinhua in a recent interview.
Noting that China is a global leader in healthcare innovation, she said the number of medicines developed in China at AstraZeneca has doubled over the last four years.
The company's local footprint has grown substantially since entering the Chinese market in 1993. It has established global production hubs in the cities of Wuxi, Taizhou and Qingdao, which supply high-quality medicines to more than 70 markets worldwide.
Earlier this year, the company announced an investment of $2.5 billion to establish a global strategic R&D center in Beijing, following the one set up in Shanghai a few years ago.
AstraZeneca's push in China aligns with its broader goals to help advance the Healthy China 2030 initiative and expand access to quality healthcare. Focusing on therapeutic areas where Chinese patients have the most urgent needs, it has introduced over 40 innovative drugs to China.
Collaboration with Chinese innovators is also a key component of AstraZeneca's strategy. Over the past two years, it has signed global licensing agreements with 14 Chinese biotech companies. Through its healthcare investment fund, the company is also supporting 27 Chinese biotechs in their global expansion efforts.
These progresses, she noted, reflect AstraZeneca's "sustained commitment to China and our confidence in its innovation."
The company has attended the China International Supply Chain Expo for three consecutive years, highlighting its China partnership and vision for a sustainable, healthy future.
"We truly believe that China's innovation in the healthcare space can make a huge impact to tackle global healthcare challenges in the years to come," she added.
胃胀吃什么药好 | 撩 是什么意思 | 正处级是什么级别 | 猫癣用什么药 | 洗银水是什么成分 |
韶关有什么特产 | 168红包代表什么意思 | 血压偏低吃什么东西补最好 | 嘴巴苦是什么原因引起的 | 口僻是什么病 |
霸王硬上弓什么意思 | 虚恋是什么意思 | 叶倩文属什么生肖 | 饸饹是什么 | 什么茶可以减肥消脂 |
爸爸的姐姐应该叫什么 | 水瓶后面是什么星座 | 晚上八点半是什么时辰 | 农历七月二十什么日子 | 手指甲紫色是什么原因 |
脸上不出汗是什么原因bfb118.com | 什么水果含硒量最高hcv8jop2ns3r.cn | 肠息肉是什么原因引起的520myf.com | 看走眼是什么意思hcv9jop0ns3r.cn | 拔完牙可以吃什么hcv8jop1ns8r.cn |
肺结节是什么原因hcv8jop9ns0r.cn | 冰丝是什么面料hcv9jop2ns8r.cn | 出生医学证明有什么用hcv7jop9ns9r.cn | 肺炎支原体阳性是什么意思hcv8jop5ns4r.cn | 神经性头疼吃什么药hcv7jop6ns2r.cn |
中午12点半是什么时辰hcv8jop0ns5r.cn | 数字8五行属什么hcv9jop0ns8r.cn | 瞿读什么hcv8jop2ns9r.cn | 小粉是什么粉hcv9jop1ns9r.cn | 不一般是什么意思hcv8jop7ns3r.cn |
八一建军节是什么节日hcv8jop5ns7r.cn | 什么车子寸步难行脑筋急转弯hcv7jop6ns8r.cn | 传导阻滞是什么意思hcv7jop9ns3r.cn | 高血压降不下来是什么原因jasonfriends.com | 朝鲜人一日三餐吃什么hcv9jop3ns8r.cn |